Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

TriSalus Life Sciences Q2 2024 GAAP EPS $(0.21) Beats $(0.41) Estimate, Sales $7.36M Inline

Author: Benzinga Newsdesk | August 15, 2024 08:02am
TriSalus Life Sciences (NASDAQ:TLSI) reported quarterly losses of $(0.21) per share which beat the analyst consensus estimate of $(0.41) by 48.78 percent. The company reported quarterly sales of $7.36 million which met the analyst consensus estimate. This is a 59.67 percent increase over sales of $4.61 million the same period last year.

Posted In: TLSI


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist